CRA provided expert testimony in litigation involving allegations that fraudulent reporting of list prices by pharmaceutical manufacturers affected reimbursement by insurers. CRA’s analyses addressed important features underlying pricing and reimbursement in the pharmaceutical industry, including the role of list prices and price reporting publications, the evolution of pricing mechanisms as a basis for reimbursement, and information held by various parties concerning pharmaceutical acquisition costs.
The future of Prescription Drug Affordability Boards (PDABs)
The effectiveness and impact of the UPL implementation for Enbrel will have a strong influence on how Maryland and other states proceed with their UPL...